2026 Update: PSDS & IETF closed. AIA gives 100% year-one relief on solar. 2026 active stack still delivers 40–60% effective subsidy. See 2026 grants →

UK pharma solar — May 2026

Solar for UK pharmaceutical manufacturing — funding routes and GMP-compliant delivery.

UK pharma manufacturing is among the most electricity-intensive industrial sectors. With Scottish IETF still active and the Annual Investment Allowance permanent, multi-MWp pharma solar projects continue to deliver 4-6 year payback alongside critical resilience benefits.

Independent
180+
Projects
£42m
Secured
4.5yr
Avg Payback
MCS NICEIC RECC TRUSTMARK

UK pharma manufacturing — exceptional solar economics with operational complications

UK pharmaceutical manufacturing has substantial decarbonisation pressure and unusually strong solar economics. Three structural drivers: (1) electricity demand is exceptional — purification, cleanroom HVAC, sterilisation and cold chain all require continuous high electricity loads; (2) operational continuity is 24/7, producing self-consumption rates of 85-95% on properly sized PV systems; (3) major UK pharma manufacturers have public net zero commitments backed by substantial capital programmes.

The complications are operational rather than economic. GMP compliance affects how PV install can be sequenced around production schedules. Cleanroom HVAC plant on the roof reduces useful unobstructed area for PV. And the cold chain criticality of many pharma processes means solar plus battery integration becomes a resilience question, not just an economic one.

The 2026 funding stack for UK pharma manufacturing

Scottish pharma (GSK Montrose, Piramal Grangemouth, others)

SIETF remains active and is the strongest direct grant route. Up to 30% of capex (50% for deep decarbonisation including process electrification). Stack with the Annual Investment Allowance on net of grant + 0% VAT + SEG.

English pharma (the majority of UK pharma)

English IETF closed for new applications. Active stack: AIA + 0% VAT + SEG + PPA + (for sites in eligible Mayoral Authority areas) Local Growth Fund. PPA is the dominant route at multi-MWp scale because of operator covenant strength.

Welsh and NI pharma

Welsh Industrial Decarbonisation (Welsh sites) and Invest NI Capital Grants (Almac, Norbrook). Both have funded several pharma manufacturing decarbonisation packages since 2022.

Major UK pharma manufacturers and their solar programmes

GSK

UK manufacturing sites include Barnard Castle (antibiotics, respiratory), Ulverston (vaccines), Ware (consumer healthcare), Worthing (oncology), Stevenage (R&D + commercial), Montrose (Scotland — APIs). Multi-site PV programme since 2022 funded through internal capital and IETF Phase 2/3 (where active). Multiple sites with multi-MWp solar deployment.

AstraZeneca

UK manufacturing at Macclesfield (oncology, cardiovascular), Luton (respiratory), Speke (small molecules). New Cambridge Discovery Centre opened with substantial integrated PV. Multi-site UK PV programme.

Pfizer

Sandwich (UK R&D and commercial). Solar deployment progressing under Pfizer global net zero commitment.

Eli Lilly

Speke (one of the largest UK pharma manufacturing sites — cytostatic injectables, insulin). PV deployment progressing since 2022 under combination of internal capital and IETF Phase 2.

Almac Group (Northern Ireland)

Craigavon (NI) and Edinburgh (Scotland) sites. Solar at both. Funded under DfE-administered NI Industrial Energy Transformation Programme and SIETF.

UK pharma supply chain

Tier-2 and tier-3 pharma suppliers — API manufacturers (Cambrex, Sterling Pharma, Dextra Labs), packaging specialists, cold-chain logistics, formulation specialists. Often more accessible for active 2026 funding routes than the major branded manufacturers (less internal capital availability, more grant dependency).

Worked example — UK pharma manufacturing site 2026

A typical UK pharma manufacturing site (formulation, packaging, distribution): 12 GWh/year electricity demand, 22,000 m² rooftop:

  • System size: 1.8 MWp rooftop + 800kWh battery (cold-chain resilience)
  • Headline capex: £1.32m PV + £360k battery = £1.68m total
  • Annual Investment Allowance on full capex: £420,000 (25%)
  • 0% VAT applied at install
  • Net cost: £1.26m
  • Annual savings (electricity displacement + SEG export): £385,000
  • Payback: 3.3 years
  • Battery resilience: 4-6 hours of cold-chain backup at typical refrigeration load

GMP compliance and install sequencing

Pharma manufacturing PV installs need GMP-aware contracting. Specifically:

  • Roof access scheduling around production batch cycles
  • Risk assessment for any ingress points near GMP areas
  • Validation requirements for changes to electrical infrastructure feeding production areas
  • Cleanroom HVAC plant — solar mounting must not interfere with airflow, particulate filtration access, or exhaust paths
  • Audit trail documentation for the install

We work with MCS-certified installers who have GMP delivery experience — the bench is small but each major UK pharma manufacturing region has at least one capable EPC.

Related sector pages

Pharma manufacturing solar FAQs

Are UK pharmaceutical manufacturers eligible for solar grants in 2026?
Scottish pharma manufacturers (GSK Montrose, Piramal Grangemouth, Pfizer Sandwich-equivalent Scottish ops) are eligible for SIETF up to 30% of capex (50% deep decarbonisation). English pharma (the majority of UK pharma — GSK Worthing/Ware/Stevenage, AstraZeneca Macclesfield/Cambridge, Pfizer Sandwich) lost direct IETF eligibility when Phase 3 closed Spring 2024. Active English pharma routes: the Annual Investment Allowance (25% via tax), 0% VAT, PPAs at scale. Welsh pharma uses Welsh Industrial Decarbonisation; Northern Irish pharma (Almac, Norbrook) uses Invest NI Capital Grants.
What size solar PV does pharma manufacturing need?
Pharma manufacturing electricity demand is exceptional — purification, cleanroom HVAC (HEPA filtration runs 24/7), refrigeration for raw materials and finished product, sterilisation. A typical UK pharma manufacturing site uses 5-30 GWh/year. On-site solar PV typically targets 5-15% of annual demand because of roof area constraints and cleanroom plant on the roof. Typical pharma solar projects 500kWp-3MWp + ground-mount where adjacent land is available.
Why are pharma manufacturing sites unusual for solar?
Three specific complications. (1) GMP compliance — pharma manufacturing is regulated under MHRA / FDA / EMA Good Manufacturing Practice; any infrastructure work near production areas requires GMP-aware contracting and validation. (2) Cleanroom plant on roof — pharma manufacturing roofs typically host substantial HVAC, particulate filtration and process plant, reducing useful unobstructed roof area for PV. (3) Cold chain criticality — many pharma processes have strict temperature stability requirements; solar power continuity through grid disturbances becomes a UPS / resilience question, not just an economic one.
Have major UK pharma manufacturers deployed solar?
Yes — extensively. GSK has solar at multiple UK manufacturing sites including Barnard Castle, Ulverston and Ware. AstraZeneca runs a major UK PV programme across Macclesfield, Luton, Speke and the new Cambridge Discovery Centre. Pfizer has Sandwich PV. Eli Lilly Speke (one of the largest UK pharma manufacturing sites) has been progressing PV since 2022. Almac Group (NI) has solar at its Craigavon and Edinburgh sites. The UK Tier-1 pharma manufacturer ecosystem is several years into multi-MWp PV deployment.
Can pharma supply chain access solar funding?
Yes — and the supply chain is often the more accessible part of the funding stack. Tier-2 and tier-3 pharma suppliers — API manufacturers, packaging operators, cold-chain logistics, formulation specialists — typically meet IETF energy intensity thresholds (where IETF was active) and continue to qualify for SIETF (Scotland), Welsh and NI equivalents. The English pharma supply chain (post-IETF closure) uses AIA + PPA for solar deployment.
How does battery storage fit pharma manufacturing solar?
Strong fit. Pharma manufacturing has continuous high electricity demand (24/7 cleanroom HVAC + cold chain refrigeration), so battery captures generation that would otherwise export and uses it overnight. Adding 200-500kWh battery to a 500-1MWp PV system typically lifts self-consumption from 80% to 92-95%. Battery is also AIA-eligible. For pharma sites with critical cold chain, solar+battery+UPS integration creates a resilience asset alongside the economic case.
Free funding review

See which grants your business qualifies for — free 20-minute funding review.

Tell us your sector, roof size and energy spend. We come back within one working day with a shortlist of grants and the realistic capex you can expect to recover.

Start Funding ReviewCall 020 4525 6101

No obligation. We don't charge for grant scoping.

Funding by asset class

The allowance depends on the asset, and most pages on this topic get it the wrong way round. Solar PV is special-rate expenditure (HMRC Capital Allowances Manual CA22335), so the 100% year-one route is the Annual Investment Allowance — Full Expensing is a main-rate measure and does not reach it. Battery storage, EV charging and heat pumps are main-rate plant, so Full Expensing genuinely does apply to those.

Free funding review

Find out which 2026 schemes your site actually qualifies for

What you get, within one working day
  • 1. A short written funding note naming every scheme your site qualifies for in 2026 — and the ones it does not.
  • 2. Indicative system size and a capex band for your roof.
  • 3. Year-one tax treatment per asset in £ — solar is special-rate expenditure, so the route is the Annual Investment Allowance; battery storage and heat pumps are main-rate plant, where Full Expensing does apply. Most pages get this the wrong way round.
  • 4. Projected SEG export revenue at current rates.
  • 5. Any red-flag eligibility or DNO issues we can see up front.

Covers solar PV, battery storage, EV charging and commercial heat pumps — separately or as one bundled project. If your project is a heat pump or a battery rather than a roof, say so in the message box and the note is written against that asset instead.

What we will not do
  • · We do not pass your details to multiple installers.
  • · We do not run a lead auction, and we never ask for your phone number.
  • · No marketing lists, no unsolicited calls.
  • · We are an independent funding consultancy — not an installer, and we take no installer commission.

Five questions. They are the eligibility test itself — scheme eligibility in 2026 turns on sector, tenure, site size and spend, so we cannot shortlist anything without them.

We reply from funding@commercialsolargrants.co.uk. No phone number required, ever.

Explore this guide cluster

Commercial solar by industry

Sector-specific solar economics — roof inventory, demand profile and the grants that apply to your industry.

Pillar guideSolar by industry & sectorEvery sector we cover, in one place. See all 29 sectors